Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 0.74 |
| ▸ | ROR1 | Q01973 | 2/20 | 0.66 |
| ▸ | CSF1R | P07333 | 2/20 | 0.61 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.58 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.58 |
| ▸ | GAK | O14976 | 1/20 | 0.58 |
| ▸ | MLNR | O43193 | 1/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 1/20 | 0.58 |
| ▸ | YES1 | P07947 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16644583 | 0.89 | ROR1 (0.67) | ABL1ROR1CSF1RCYP3A4KCNH2 | |
| SCHEMBL27149597 | 0.85 | ABL1 (1.00) | ABL1ROR1CSF1RDDR1DDR2 | |
| SCHEMBL30010331 | 0.85 | ABL1 (1.00) | ABL1ROR1CSF1RDDR1DDR2 | |
| SCHEMBL16644465 | 0.84 | ABL1 (1.00) | ABL1ROR1CSF1RDDR1DDR2 | |
| SCHEMBL16644461 | 0.84 | ABL1 (0.84) | ABL1ROR1CSF1RDDR1DDR2 | |
| SCHEMBL30788441 | 0.84 | ABL1 (0.80) | ABL1ROR1CSF1RDDR1DDR2 | |
| SCHEMBL30788442 | 0.83 | ABL1 (0.79) | ABL1ROR1CSF1RDDR1DDR2 | |
| SCHEMBL30788453 | 0.83 | ABL1 (0.79) | ABL1ROR1CSF1RDDR1DDR2 | |
| SCHEMBL31544608 | 0.83 | ABL1 (0.79) | ABL1ROR1CSF1RDDR1DDR2 | |
| SCHEMBL30788446 | 0.83 | ABL1 (0.78) | ABL1ROR1CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | ARIAD PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | ARIAD PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | BRAF, RAF1, NRAS | ABL1 75/4885ROR1 263/4885CSF1R 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.